Patent Prosecution at KIPI for Life Sciences and Biotech Inventions

Patent prosecution at KIPI is the gateway a life sciences or biotech company must pass through before a diagnostic method, a drug formulation or a device mechanism can be protected by a Kenyan patent. Filing under the Patent Cooperation Treaty (PCT) does not by itself create Kenyan protection, because the PCT is a filing system and not a granting authority. This article walks through the Kenyan route under the Industrial Property Act, 2001 (Cap. 509): the application, the examination timeline, the PCT and ARIPO routes, protection terms, the biotech exclusions, and the local agent requirement.

Filing the application

Under section 34 of the Act, an application for a patent is filed with the Managing Director of the Kenya Industrial Property Institute (KIPI). It must contain a request, a description, one or more claims, drawings where necessary, and an abstract. The description must disclose the invention and the best mode for carrying it out. Section 41 provides for the filing date and examination of the application as to form, so a formal check comes first.

Examination and publication timeline

Substantive examination, which assesses whether the invention is patentable, is not automatic. Section 44 requires the applicant to submit a request in the prescribed form for examination within five years from the filing date of the application. Where no request is made within the prescribed period, the application is deemed abandoned. Older commentary that refers to a three-year window does not match the current text of the section. On examination, the Managing Director assesses whether the invention is patentable, whether the application complies with the section 34 requirements, and whether it meets the requirement of unity of invention in section 35.

Publication is separate. Under section 42, the Managing Director publishes the application as soon as possible after eighteen months from the filing date, or from the priority date where priority is claimed. The applicant may request earlier publication. Unless the application is rejected or a patent refused under section 41 or 44, a patent is granted, registered and published under section 45. A pharmaceutical or biotech applicant racing a competitor should request examination early rather than waiting for the deadline.

PCT and ARIPO routes into Kenya

Part VI of the Act deals with international applications under the PCT, and the PCT national phase is a route into Kenya, but the grant is still made under the Kenyan Act.

For the regional route, section 59 provides that the Institute acts as a receiving office and as a designated office where Kenya is designated in a regional application under the Harare Protocol. Under section 59(5), a patent, utility model or industrial design granted or registered under the Harare Protocol in which Kenya is designated is treated as if it were granted or registered under the Act. Under section 59(6), the owner has the same rights and remedies, and the Act’s provisions on surrender, revocation, infringement and rectification of registers apply with necessary modifications. Commentary elsewhere refers to a right of the Managing Director to declare a contrary opinion. We did not find that opt-out in the text of section 59 as published by Kenya Law, so check the current Harare Protocol and ARIPO position for your specific patent with counsel before relying on either description.

Protection terms

A patent expires at the end of twenty years from the filing date of the application (section 60). Utility model certificates expire at the end of the tenth year after the filing date and are not renewable. An industrial design registration lasts until the end of the fifth year after the application date and can be renewed for two further consecutive periods of five years on payment of the prescribed fee (section 88), which gives a maximum of fifteen years. These terms are hard limits, so a licensing or investment model built around one compound or device should plan for the cliff edge.

Exclusions that matter in life sciences

The Act excludes from patent protection inventions that are contrary to public order, morality, public health and safety, principles of humanity and environmental conservation. For biotech and pharmaceutical applicants, this is a policy ground for refusal that a mechanical engineering applicant seldom meets, and it should be assessed with counsel before filing, not discovered at examination.

Trade secrets are a possible complement or alternative for manufacturing processes and formulations that are difficult to reverse-engineer. Protection lasts only while the information stays confidential, and there is no register or filing date to rely on in a dispute. Where publication of the application would itself harm the business, weigh that option against filing.

The local agent requirement

Section 34(2) provides that where the applicant’s ordinary residence or principal place of business is outside Kenya, the applicant shall be represented by an agent who is a citizen of Kenya admitted to practise before the Institute. A foreign life sciences company therefore cannot file directly through its home counsel. Prosecution correspondence runs through the Kenyan agent, and the appointment is evidenced by a power of attorney signed by the applicant (section 34(4)). Choose the agent as you would any other advisor, because they will manage office actions and your deadlines.

After grant

A granted patent can still be attacked. The Act contains revocation provisions, and a patent granted through ARIPO is subject to them as well under section 59(6). Prior art searching before filing, and a clear record of the inventive step, are the best protection. For commercial exploitation of a granted patent, including the licence registration and prohibited terms regime in sections 68 to 70, see our guide to technology transfer and licensing agreements in life sciences.